Mepivacaine

Verify with FDA CVM →

14 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
3
Deaths Reported
2140.0%
Death Rate

Active Ingredients

Mepivacaine

Administration Routes

UnknownParenteralIntra-ArticularIntraocularOral

Species Affected

Cat 10
Horse 2
Dog 1
Cattle 1

Most Affected Breeds

Domestic Shorthair 6
Cat (unknown) 2
Crossbred Equine/horse 1
Dachshund (unspecified) 1
Domestic Longhair 1
Cattle (other) 1
Horse (other) 1
Domestic Mediumhair 1

Most Reported Reactions

Uncoded sign 5
Hiding 5
Dysphoria 4
Hyperactivity 3
Vocalisation 3
Dilated pupils 3
Not eating 3
Constipation 3
Increased heart rate 2
Elevated aspartate aminotransferase (AST) 2
Elevated temperature 2
Hypoalbuminaemia 2

Outcome Breakdown

Ongoing
5 (35.7%)
Recovered/Normal
4 (28.6%)
Died
2 (14.3%)
Outcome Unknown
2 (14.3%)
Euthanized
1 (7.1%)

Data Summary

Metric Value
Total adverse event reports 14
Reports involving death 3
Case-fatality rate (reported events) 2140.0%
Distinct species in reports 4
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Mepivacaine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 14 adverse event reports referencing Mepivacaine, including 3 reports in which the animal died — a 2140.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Mepivacaine. Reported administration routes include Unknown, Parenteral, Intra-Articular, Intraocular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Mepivacaine reports are Cat (10 reports), Horse (2 reports), Dog (1 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (6), Cat (unknown) (2), Crossbred Equine/horse (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Mepivacaine are Uncoded sign (5), Hiding (5), Dysphoria (4), Hyperactivity (3). Of the 14 reports with a coded outcome, Ongoing is the leading category at 35.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Mepivacaine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial